Pirenoxine
Title: Pirenoxine
CAS Registry Number: 1043-21-6
CAS Name: 1-Hydroxy-5-oxo-5H-pyrido[3,2-a]phenoxazine-3-carboxylic acid
Additional Names: 1-hydroxy-5H-pyrido[3,2-a]phenoxazin-5-one-3-carboxylic acid; 1-hydroxy-3-carboxy-5H-pyrido[3,2-a]phenoxazin-5-one; pirfenoxone
Trademarks: Catalin (Senju)
Molecular Formula: C16H8N2O5
Molecular Weight: 308.25
Percent Composition: C 62.34%, H 2.62%, N 9.09%, O 25.95%
Literature References: Prepn: S. Ogino, JP 59 2227, C.A. 54, 11058i (1960); S. Ishii, JP 61 1782, C.A. 55, 21494e (1961) (1959, 1961 both to Chizu Drug); of the sodium salt: S. Ishii, K. Ogata, JP 73 2672 (1973 to Senju), C.A. 80, 6959t (1974). Pharmacological studies: F. Ikemoto et al., Oyo Yakuri 8, 937 (1974), C.A. 83, 71663t (1975). Toxicological studies: eidem, ibid. 911, 923, C.A. 82, 51617g, 68262k (1975). Influence on carbohydrate metabolism in the lens: I. Korte et al., Ophthalmic Res. 7, 282 (1975). Effect on NADH, NADPH: eidem, ibid. 440. Effect on senile cataracts: T. Murata, Folia Ophthalmol. Jpn. 31, 1217 (1980). Clinical trial in treatment of cataracts: S. K. Angra et al., Indian J. Ophthalmol. 31, 5 (1983).
Properties: Orange-yellow powder, mp 247-248° (dec).
Melting point: mp 247-248° (dec)
 
Derivative Type: Sodium salt
CAS Registry Number: 51410-30-1
Trademarks: Clarvisan (Allergan)
Molecular Formula: C16H7N2NaO5
Molecular Weight: 330.23
Percent Composition: C 58.19%, H 2.14%, N 8.48%, Na 6.96%, O 24.22%
Properties: Very sol in water. LD50 in mice (mg/kg): >10000 orally; >5000 s.c.; 2120-2250 i.p. LD50 in rats (mg/kg) i.p.: 2400 (males); 1460 (females) (Ikemoto).
Toxicity data: LD50 in mice (mg/kg): >10000 orally; >5000 s.c.; 2120-2250 i.p. LD50 in rats (mg/kg) i.p.: 2400 (males); 1460 (females) (Ikemoto)
 
Therap-Cat: Treatment of cataracts.

Others monographs:
Methyl FormatePropylenediamineL-Tartaric AcidN-Methyltaurine
Calciseptinen-ButylamineCefpimizolePhthalamide
Fumonisin B1Uridine 5'-DiphosphateBacitracin MethylenedisalicylateGeosmin
PramipexoleCarbanilideNeopterinAmmonium Osmium Chloride
©2016 DrugLead US FDA&EMEA